Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Inclusion Criteria:

* 18 years of age or older
* Patients with previously untreated WM and those who have received prior therapy are eligible
* Must have received prior therapy for their WM and have relapsed or refractory WM.
* CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed up to 3 months prior to enrollment.
* Measurable disease
* ECOG Performance Status 0,1, or 2
* Total bilirubin \< 2.0 mg/dl
* AST \< 3 x ULN
* Life expectancy of greater than 12 weeks

Exclusion Criteria:

* Uncontrolled infection
* Other active malignancies
* Cytotoxic chemotherapy less than 3 weeks, or biologic therapy less than 2 weeks, or corticosteroids less than 2 weeks, prior to registration.
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational
* Known to be HIV positive or HEP B positive
* Radiation therapy less than 2 weeks prior to registration
* Grade 2 or greater peripheral neuropathy
* Myocardial infarction within 6 months rior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
* Hypersensitivity to bortezomib, boron, or mannitol
* Pregnant or breast feeding women
* Other investigational drugs within 14 days of enrollment
* Serious medical or psychiatric illness likely to interfere with participation